RSCM
CMPX icon

Rock Springs Capital Management’s Compass Therapeutics CMPX Stock Holding History

Rock Springs Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.72M Buy
3,524,929
+219,621
+7% +$648K 0.38% 62
2026
Q1 		$17.5M Sell
3,305,308
-621,894
-16% -$3.59M 1.03% 33
2025
Q4 		$21.1M Sell
3,927,202
-547,500
-12% -$2.53M 1.08% 30
2025
Q3 		$15.7M Sell
4,474,702
-488,253
-10% -$1.54M 0.92% 36
2025
Q2 		$12.9M Hold
4,962,955
– – 0.8% 44
2025
Q1 		$9.43M Sell
4,962,955
-816,620
-14% -$2.17M 0.54% 53
2024
Q4 		$8.38M Buy
5,779,575
+150,336
+3% +$250K 0.32% 67
2024
Q3 		$10.4M Buy
5,629,239
+115,451
+2% +$144K 0.34% 68
2024
Q2 		$5.51M Hold
5,513,788
– – 0.17% 82
2024
Q1 		$10.9M Hold
5,513,788
– – 0.28% 75
2023
Q4 		$8.6M Hold
5,513,788
– – 0.21% 73
2023
Q3 		$10.9M Hold
5,513,788
– – 0.29% 71
2023
Q2 		$17.5M Hold
5,513,788
– – 0.42% 62
2023
Q1 		$18M Buy
5,513,788
+180,600
+3% +$709K 0.43% 61
2022
Q4 		$26.8M Hold
5,333,188
– – 0.65% 50
2022
Q3 		$12.2M Buy
5,333,188
+5,100
+0.1% +$14.1K 0.31% 71
2022
Q2 		$14.1M Hold
5,328,088
– – 0.41% 64
2022
Q1 		$7.3M Hold
5,328,088
– – 0.18% 94
2021
Q4 		$16.9M Buy
+5,328,088
New +$17.7M 0.39% 73

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rock Springs Capital Management's CMPX Position: Q2 2026 in Review

Rock Springs Capital Management increased its Compass Therapeutics (CMPX) stake by 6.6% in Q2 2026, buying an estimated $648K and bringing the position to 3,524,929 shares worth $7.72M. The position accounts for 0.38% of the portfolio, ranked #62.

Rock Springs Capital Management first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $26.8M in Q4 2022. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Rock Springs Capital Management held 3,524,929 shares of Compass Therapeutics worth $7.72M as of Q2 2026.
  • Rock Springs Capital Management bought 219,621 Compass Therapeutics shares in Q2 2026, an estimated $648K.
  • Compass Therapeutics made up 0.38% of Rock Springs Capital Management's portfolio in Q2 2026, its #62 holding.
  • Rock Springs Capital Management first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Rock Springs Capital Management's Compass Therapeutics position peaked at $26.8M in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.